WO2002060474A2 - Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion - Google Patents
Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion Download PDFInfo
- Publication number
- WO2002060474A2 WO2002060474A2 PCT/EP2002/000374 EP0200374W WO02060474A2 WO 2002060474 A2 WO2002060474 A2 WO 2002060474A2 EP 0200374 W EP0200374 W EP 0200374W WO 02060474 A2 WO02060474 A2 WO 02060474A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fip
- lipase
- amylase
- protease
- enzymes
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 69
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 201000006549 dyspepsia Diseases 0.000 title claims abstract description 14
- 235000001674 Agaricus brunnescens Nutrition 0.000 title description 4
- 108010065511 Amylases Proteins 0.000 claims abstract description 51
- 102000013142 Amylases Human genes 0.000 claims abstract description 51
- 102000004882 Lipase Human genes 0.000 claims abstract description 48
- 108090001060 Lipase Proteins 0.000 claims abstract description 48
- 235000019418 amylase Nutrition 0.000 claims abstract description 48
- 239000004382 Amylase Substances 0.000 claims abstract description 45
- 239000004367 Lipase Substances 0.000 claims abstract description 45
- 235000019421 lipase Nutrition 0.000 claims abstract description 45
- 108091005804 Peptidases Proteins 0.000 claims abstract description 39
- 239000004365 Protease Substances 0.000 claims abstract description 39
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 19
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 241000981399 Aspergillus melleus Species 0.000 claims abstract description 9
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims abstract description 9
- 241000303962 Rhizopus delemar Species 0.000 claims abstract description 9
- 238000011321 prophylaxis Methods 0.000 claims abstract description 9
- 240000006439 Aspergillus oryzae Species 0.000 claims abstract description 8
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims abstract description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 8
- 230000000694 effects Effects 0.000 claims description 41
- 235000019419 proteases Nutrition 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000008188 pellet Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 8
- 102000035092 Neutral proteases Human genes 0.000 claims description 6
- 108091005507 Neutral proteases Proteins 0.000 claims description 6
- 108090000145 Bacillolysin Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- -1 sachets Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000012055 enteric layer Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 abstract description 13
- 229940088598 enzyme Drugs 0.000 description 58
- 229940040461 lipase Drugs 0.000 description 35
- 102000035195 Peptidases Human genes 0.000 description 31
- 238000006467 substitution reaction Methods 0.000 description 29
- 239000000243 solution Substances 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 102000038379 digestive enzymes Human genes 0.000 description 21
- 108091007734 digestive enzymes Proteins 0.000 description 21
- 238000012360 testing method Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- 108010019160 Pancreatin Proteins 0.000 description 14
- 229940055695 pancreatin Drugs 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 210000000941 bile Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 235000019621 digestibility Nutrition 0.000 description 8
- 229910021642 ultra pure water Inorganic materials 0.000 description 8
- 239000012498 ultrapure water Substances 0.000 description 8
- 239000000306 component Substances 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 238000009533 lab test Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000003833 bile salt Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 210000004913 chyme Anatomy 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 235000019626 lipase activity Nutrition 0.000 description 4
- 230000002366 lipolytic effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 3
- 235000019888 Vivapur Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940025131 amylases Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 235000010633 broth Nutrition 0.000 description 3
- 235000019784 crude fat Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 108010079522 solysime Proteins 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 240000005384 Rhizopus oryzae Species 0.000 description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003625 amylolytic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000277 pancreatic duct Anatomy 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000588264 Rhizopus javanicus Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 108010051873 alkaline protease Proteins 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000007089 exocrine pancreatic insufficiency Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
Definitions
- the present invention relates to new enzyme mixtures which contain a certain combination of microbial lipase, protease and amylase. Furthermore, the invention relates to pharmaceutical preparations containing these mixtures of microbial enzymes. These new pharmaceutical preparations are particularly well suited for the treatment and / or prophylaxis of maldigestion in mammals and humans, in particular for the treatment and / or prophylaxis of maldigestion based on chronic exocrine pancreatic insufficiency.
- pancreatic insufficiency the organ that produces the most important endogenous digestive enzymes. If there is pathological pancreatic insufficiency, this can be congenital or acquired. Acquired chronic pancreatic insufficiency can be due to alcoholism, for example. Congenital pancreatic insufficiency can, for example, be due to the congenital disease of cystic fibrosis.
- the consequences of the lack of digestive enzymes can be severe symptoms of malnutrition and malnutrition, which can be associated with an increased susceptibility to secondary diseases.
- pancreatin preparations intended for oral administration should be coated with gastro-resistant protective layers to protect against acid-induced denaturation in the stomach.
- gastro-resistant protective layers protect the acid-sensitive pancreatin components from irreversible destruction and only release their contents after passage through the stomach in the upper part of the small intestine, where usually higher, harmless pH values - for example between pH 5.5 and pH 8 - prevail.
- the upper part of the small intestine for example the duodenum, is the place where the majority of the enzymatically split food components are usually absorbed by the body.
- pancreatin Since pancreatin is a natural product, it requires a considerable amount of technical effort to provide it in a uniform, high-quality form. In addition, the supply of raw materials suitable for processing into pancreatin can fluctuate.
- substitution enzymes In order to be suitable for the substitution of digestive enzymes in humans, all substitution enzymes must be one Fulfill a number of requirements (see, for example, BG Peschke, "Active Components and Galenic Aspects of Enzyme Preparations" in: Pancreatic Enzymes in Health and Disease, publisher: PG Lankisch, Springer Verlag Berlin, Heidelberg 1991, pages 55 to 64; hereinafter cited as “Peschke”).
- these substitution enzymes should be stable to pepsin and other endogenous proteases such as pancreatic proteases. Substitution enzymes should remain active even in the presence of the body's bile salts.
- the various substitution enzymes contained in the pharmaceutical preparation are able to develop their activities in sufficient amounts at the intended site of action (which is usually the upper part of the small intestine). Since under physiological conditions during or shortly after the food intake in the human stomach there is usually a higher pH value, for example pH 4-5, than in the empty stomach (approx.
- the object of the present invention was therefore to provide improved mixtures of digestive enzymes and pharmaceutical compositions containing such mixtures for the treatment and / or prophylaxis of maldigestion in mammals and humans which can substitute the body's own lipolytic, proteolytic and amylolytic enzyme activities and which can be more specific Activity of the substitution enzymes contained therein allow relatively small dosage amounts.
- the substitution enzymes contained in the digestive enzyme mixtures lipase, protease, amylase), both individually and in a mixture with one another, should meet as well as possible all the requirements which are placed on digestive enzymes intended for therapy in humans.
- the substitution enzymes should have good pH stability and good pH activity in the pH range usually prevailing at the respective physiological site of action.
- substitution enzymes should be well tolerated with endogenous active substances such as bile salts or endogenous proteases, for example pepsin or pancreatic proteases. Another object was to select, for the purpose according to the invention, those substitution enzymes which can be obtained in manufacturing quality which can always be standardized in terms of process sequence and product quantity and which can always be of constant quality and in any quantity.
- the task is solved by providing a new mixture of microbial enzymes, which
- a) a concentrated lipase from Rhizopus delemar, b) a neutral protease from Aspergillus melleus and c) an amylase from Aspergillus oryzae contains.
- Mixtures of microbial enzymes according to the invention can be contained in conventional pharmaceutical preparations together with customary auxiliaries and / or carriers. These pharmaceutical preparations contain only mixtures according to the invention of microbial enzymes of certain molds as active substances and are suitable for the total substitution of the body's own digestive enzymes from mammals and humans.
- the individual enzymes (lipase, protease, amylase) contained in the mixture of microbial enzymes according to the invention have in common that they are in the physiological to pathophysiological pH range of the digestive tract (approximately pH 4 to 8) and in particular below those at or shortly after eating prevailing conditions have good pH stability and good pH activity.
- the pharmaceutical preparations are also characterized by good effectiveness and good tolerability.
- the Rhizopus delemar strain is considered a subspecies of the Rhizopus oryzae strain. Lipases from molds of the Rhizopus delemar strain are known per se and can be used e.g. B. can be obtained by per se known methods from culture broths of the corresponding mushroom. Processes for the fermentation of molds and for the isolation of the enzyme products formed by these molds are known to the person skilled in the art, for example from relevant textbooks in biotechnology (cf., for example, H. Diekmann, H.
- the isolated lipases z. B. freed from accompanying substances in a manner known per se and enriched or concentrated to the specific activity desired according to the invention.
- the lipase (EC No. 3.1.1.3) "Lipase D Amano 2000 ® “(also referred to as” Lipase D2 ® ) from Rhizopus delemar from Amano Pharmaceuticals, Japan.
- This lipase like the natural pancreatic lipase, has a 1,3-position specificity compared to fatty acid glycerides specific activity, depending on the batch, is between approximately 1,800,000 FIP-E / g and approximately 2,250,000 FIP-E / g.
- "Lipase D Amano 2000 ®” is characterized by a high stability towards pancreatic protease from pancreatin the lipolytic activity of "Lipase D Amano 2000 ® " in a laboratory test after two hours of exposure to pancreatic protease from pancreatin in a pH range from pH 6 to 8 still at 55% of the initial activity.
- the pH stability of the "Lipase D Amano 2000 ® " was in a laboratory test in a pH range from pH 4 to 8 at 37 ° C over a period of 120 min with at least 70% of the initial activity.
- a concentrated lipase from Rhizopus delemar for example, its pH profile is suitable.
- the pH profile of the "Lipase D Amano 2000®” was therefore determined as a specific activity as a function of the pH.
- the specific activities at the individual pH values were measured after a modification of the FIP methods for determining the activity of microbial lipases.
- the pH profiles were also determined in the presence of variable concentrations of bile salts.
- Samples of 19 ml each at 37 ° C. are thermostatted from the above-mentioned substrate emulsions, in which certain bile salt concentrations are present.
- pH values of 3, 4, 5, 6, 7 and 8 are then set by adding 0.1 M NaOH or 1 M HCl.
- 1 ml of the above-mentioned enzyme solution is then added to the samples of substrate emulsions prepared in this way (note: in order to determine the optimal titration rate, the suitable amount of ideally contained lipase in the enzyme solution can in principle be determined in a manner known per se by means of a series of dilutions ).
- An end point titration to pH 9 is then carried out within 30 seconds in order to completely dissociate the released fatty acids.
- the total consumption of 0.1 M NaOH required is in lipase activity units E converted: a lipase activity unit E corresponds to a consumption of 1 ⁇ mol per minute.
- the lipase activity units determined can be converted into units of E / mg by referring to the amount of dry enzymes used in g. To create the pH profile, the units of E / mg for each pH value and each bile salt concentration examined are tabulated in Table 1 and the tabulated values are graphically plotted in FIG. 1.
- the pH optimum for "Lipase D Amano 2000 ®” as the maximum value of lipase activity at the FIP standard bile salt concentration of 0.5 mmol / l can be determined from the pH profile given above to be about pH 7.
- the neutral protease from Aspergillus melleus has a specific activity of at least 7,500 FIP-E / g. Their pH optimum is between pH 6 and pH 8.
- Neutral proteases of molds from the Aspergillus melleus strain are known per se and can be used e.g. B. can be obtained by per se known methods from culture broths of the corresponding mushroom. Processes for the fermentation of molds and for the isolation of the enzyme products formed by these molds are known to the person skilled in the art, for example from relevant textbooks in biotechnology (cf., for example, H. Diekmann, H. Metz, "Fundamentals and Practice of Biotechnology", Gustav Fischer Verlag Stuttgart, New York 1991) or from relevant scientific publications. If desired, the isolated proteases can then be freed of accompanying substances in a manner known per se and enriched or concentrated to the specific activity desired according to the invention.
- the neutral protease "Prozyme 6 ®” (sometimes also referred to as "alkaline proteinase", EC No. 3.4.21.63) from Aspergillus melleus from Amano Pharmaceuticals, Japan, can be used.
- This microbial Protease hydrolyzes 1,4- ⁇ -D-glucosidic bonds of polysaccharides which contain at least three 1,4-D-glucose units and has a specific activity of approximately 7,800 FIP-E / g.
- the pH stability of the protease "Process e 6 ® " in a pH range from pH 5 to 8 at 37 ° C was over a period of 120 min. in a laboratory test with at least 60% of the initial activity.
- a suitable parameter for determining a neutral protease from Aspergillus melleus is, for example, its pH profile.
- the pH profile of the protease "Prozyme 6 ®” was therefore determined as a specific activity as a function of the pH.
- various substrate solutions are produced in accordance with the regulations of the FIP method for determining the activity of pancreatic proteases.
- a 4% hemoglobin solution is used instead of casein as the substrate solution.
- different pH values of 2, 3, 4, 5, 6, 7 and 8 are set in various substrate solutions by adding appropriate amounts of IM NaOH or IM HCl. Samples of "Prozyme 6 ® " are added to the substrate solutions.
- protease activities of the "Prozyme 6 ® " samples are then determined in the substrate solutions of different pH values in accordance with the FIP regulations mentioned above.
- the measured values for the pH profile found for "Prozyme 6 ® " are tabulated in Table 2 and plotted in Fig. 2.
- "Prozyme 6 ® " is therefore optimally effective in the physiological pH range. From the pH profile given above, the pH optimum for "Prozyme 6 ® " as the maximum value of the protease activity can be determined to be approximately pH 8.
- Aspergillus oryzae amylase (EC No. 3.21.1.1) used according to the invention is an ⁇ -amylase and has a specific activity of at least 40,000 FIP-E / g (measured at pH 5.8).
- the pH optimum is in the pH range from pH 4 to 6.5.
- Amylases from molds of the Aspergillus oryzae strain are known per se and can, for. B. can be obtained by per se known methods from culture broths of the corresponding mushroom. Processes for the fermentation of molds and for the isolation of the enzyme products formed by these molds are known to the person skilled in the art, for example from relevant textbooks in biotechnology (cf., for example, H. Diekmann, H.
- amylase AI ® from Aspergillus melleus from Amano Pharmaceuticals, Japan and "Amylase EC ®” from Aspergillus melleus from E Gra-Chemie, Germany can preferably be used. "Amylase AI ® " is preferred.
- the microbial amylase "Amylase Al ®” has a specific activity of about 52,000 FIP-E / g (measured at pH 5.8).
- the pH stability of the "Amylase AI ® " in a pH range from pH 5 to 8 at 37 ° C was over a period of 120 min. in a laboratory test with at least 85% of the initial activity. In further laboratory tests, good stabilities of the "Amylase AI ® " against pancreatic protease from pancreatin (measured in the pH range pH 6 to 8), against “Prozyme 6 ® " (measured in the pH range pH 4 to 8) and against pepsin were found.
- a suitable parameter for determining an amylase from Aspergillus oryzae is, for example, its pH profile. The pH profile of the "Amylase AI ® " was therefore determined as a specific activity as a function of the pH.
- Various substrate solutions are produced in accordance with the FIP method for determining the activity of microbial amylases.
- various pH values of 3.25 each are obtained in various substrate solutions by adding appropriate amounts of 5 M NaOH or 5 M HCl to the acetate buffer used according to the FIP method; 4; 5; 6; 6.8 and 7.4 set.
- Samples of "Amylase AI ®" are added to the substrate solutions.
- amylase activities of the “Amylase Al® ” samples are then determined in substrate solutions of different pH values in accordance with the FIP regulations mentioned above.
- the measured values for the pH profile found for "Amylase AI ®" are tabulated in Table 3 and plotted in Fig. 3.
- the optimum pH for "Amylase AI ®” can be determined as the maximum value of the amylase activity at about pH 5.
- the microbial amylase "Amylase EC ®” has a specific activity of about 42,500 FIP-E / g (measured at pH 5.8). In addition, small amounts of ß-amylase are still detectable.
- the pH optimum (measured according to the method given above for Amylase AI ® ") is approximately pH 5.
- solid orally administrable dosage forms can preferably be selected, for example powders, pellets or microspheres, which, if desired, can be filled into capsules or sachets or pressed into tablets.
- Liquid pharmaceutical preparations such as suspensions or solutions may also be considered.
- the individual enzymes lipase, protease and amylase can be present together or spatially separated from one another. If the individual enzymes are not spatially separated from one another, dry processing and / or storage is preferred.
- the pharmaceutical preparations can furthermore contain customary auxiliaries and / or carriers.
- auxiliaries and / or carriers are, for example, microcrystalline celluloses, polyethylene glycols, for example PEG 4000, or else lower alcohols, in particular straight-chain or branched C 1 -C 4 alcohols such as 2-propanol, and water.
- the microbial substitution enzymes used according to the invention are notable for good stability over wide pH ranges and can therefore be used directly for the manufacture of pharmaceutical preparations to be administered orally without further treatment (such as filming).
- the individual substitution enzymes lipase, protease and amylase
- the individual substitution enzymes can be pelleted together or separately from one another.
- the individual substitution enzymes can be filmed with a suitable, known gastric juice-resistant layer. Unless all substitution enzymes are to be film-coated in gastric juice-resistant form, it is advisable to pellet the individual types of substitution enzymes separately and to film the pellets of an enzyme type separately. men.
- the protease and / or the lipase individually and to film them in an enteric coating.
- all three enzymes present in the enzyme mixture can also be film-coated together with gastric juice-resistant or two enzymes can be film-coated with gastric juice-resistant while one enzyme is not being filmed.
- the pharmaceutical preparation can be in the form of an orally administrable capsule of size 0. Even in such a dosage form there can be approximately 10,000-50,000 FIP-E lipase, 8,000 FIP-E amylase and 200 FIP-E protease.
- the substitution enzymes lipase, amylase and protease are expediently present in a ratio of approximately 50-500 FIP-E: 40-120 FIP-E: 1 FIP-E.
- the homogenate obtained was made up to a volume of 450 ml with ultrapure water.
- bile dispersion (FIP standard; lipase activation ixture) was dissolved in 50 ml of ultrapure water.
- the prepared measuring solution was heated to 37 ° C. and adjusted to pH 7 by end-point titration with 1 M NaOH. Immediately after adding the three enzyme solutions, a pH stat titration was carried out for 20 min. started and the consumption of 1 M NaOH was registered every 10 sec. During the titration, 1 ml of a 4 M calcium chloride solution was added manually in steps of 50 ⁇ l in such a way that a maximum reaction rate was achieved. F) Result
- the good fat digestion performance of a digestive enzyme mixture containing the enzymes which can be used according to the invention can also be demonstrated in vitro on an olive oil test food.
- Chymus samples were taken from the diversion cannula over 12 hours each on the 20th to 22nd day of the examination period and these were examined for their content of crude fat, crude protein and starch.
- the feeding experiments and their evaluation were carried out in a manner known per se (cf. PC Gregory, R. Tabeling, J. Kamphues, "Biology of the Pancreas in Growing Animals”; Developments in Animal and Veterinary Sciences 28 (1999) 381-394, Elsevier, Amsterdam; Ed .: SG Pierzynowski and R. Zabielski).
- precaecal digestibility The apparent precaecal digestibility of crude fat, crude protein and starch in the test animals determined in the aforementioned in vivo test is given in Table A below in percentages, based on the originally fed absolute amount of fat, protein and starch.
- the values given as “precaecal digestibility” correspond to the "apparent precaecal digestibility", which differ from the actual precaecal digestibility in that they can also contain small amounts of endogenous fractions of the investigated substances, for example endogenous proteins.
- the precaecal digestibility was determined using the following formula from the chyme of the test animals using the marker method:
- SV (%) 100 - (% indicator in the F utter% Mahrstoff in chyme 100)% indicator in chyme% nutrient in the diet
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL02362646A PL362646A1 (en) | 2001-01-19 | 2002-01-16 | Novel mixtures of microbial enzymes |
JP2002560665A JP2004524838A (ja) | 2001-01-19 | 2002-01-16 | 微生物酵素の新規混合物 |
CA002434808A CA2434808A1 (en) | 2001-01-19 | 2002-01-16 | Novel mixtures of microbial enzymes |
BR0206521-5A BR0206521A (pt) | 2001-01-19 | 2002-01-16 | Misturas de enzimas microbianas |
MXPA03005960A MXPA03005960A (es) | 2001-01-19 | 2002-01-16 | Nuevas mezclas de enzimas microbianas. |
SK929-2003A SK9292003A3 (en) | 2001-01-19 | 2002-01-16 | Novel mixtures of microbial enzymes |
KR10-2003-7009470A KR20030067752A (ko) | 2001-01-19 | 2002-01-16 | 미생물 효소의 신규 혼합물 |
EP02716661A EP1381386A2 (de) | 2001-01-19 | 2002-01-16 | Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion |
IL15700402A IL157004A0 (en) | 2001-01-19 | 2002-01-16 | Novel mixtures of microbial enzymes |
HU0500560A HUP0500560A3 (en) | 2001-01-19 | 2002-01-16 | Mixtures of mushroom enzymes and the use thereof for treating maldigestion |
NZ527148A NZ527148A (en) | 2001-01-19 | 2002-01-16 | Novel mixtures of microbial enzymes |
US10/620,759 US20040057944A1 (en) | 2001-01-19 | 2003-07-17 | Microbial enzyme mixtures useful to treat digestive disorders |
NO20033261A NO20033261D0 (no) | 2001-01-19 | 2003-07-18 | Nye blandinger av mikrobielle enzymer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10102495.9 | 2001-01-19 | ||
DE10102495 | 2001-01-19 | ||
DE10144711A DE10144711A1 (de) | 2001-01-19 | 2001-09-11 | Neue Gemische mikrobieller Enzyme |
DE10144711.6 | 2001-09-11 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/620,759 Continuation US20040057944A1 (en) | 2001-01-19 | 2003-07-17 | Microbial enzyme mixtures useful to treat digestive disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002060474A2 true WO2002060474A2 (de) | 2002-08-08 |
WO2002060474A3 WO2002060474A3 (de) | 2003-10-30 |
Family
ID=26008287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/000374 WO2002060474A2 (de) | 2001-01-19 | 2002-01-16 | Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040057944A1 (de) |
EP (1) | EP1381386A2 (de) |
JP (1) | JP2004524838A (de) |
CN (1) | CN1236817C (de) |
AR (1) | AR032392A1 (de) |
BR (1) | BR0206521A (de) |
CA (1) | CA2434808A1 (de) |
CZ (1) | CZ20031900A3 (de) |
HU (1) | HUP0500560A3 (de) |
IL (1) | IL157004A0 (de) |
MX (1) | MXPA03005960A (de) |
NO (1) | NO20033261D0 (de) |
NZ (1) | NZ527148A (de) |
PL (1) | PL362646A1 (de) |
RU (1) | RU2003124078A (de) |
SK (1) | SK9292003A3 (de) |
WO (1) | WO2002060474A2 (de) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115445A1 (en) | 2004-05-24 | 2005-12-08 | Novozymes A/S | Enzymes for pharmaceutical use |
WO2006044529A1 (en) * | 2004-10-14 | 2006-04-27 | Altus Pharmaceuticals Inc. | Compositions containing lipase; protease and amylase for treating pancreatic insufficiency |
WO2006136161A2 (en) * | 2005-06-24 | 2006-12-28 | Novozymes A/S | Amylases for pharmaceutical use |
WO2006136159A2 (en) * | 2005-06-24 | 2006-12-28 | Novozymes A/S | Lipases for pharmaceutical use |
WO2008079685A2 (en) * | 2006-12-21 | 2008-07-03 | Novozymes A/S | Lipase variants for pharmaceutical use |
WO2009083607A1 (en) * | 2008-01-03 | 2009-07-09 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders |
US7998476B2 (en) | 2006-11-22 | 2011-08-16 | Standard Biologics, Inc. | Method of treatment using Aspergillus oryzae protease |
US8455235B2 (en) | 2007-12-04 | 2013-06-04 | Novozymes A/S | Protease variants for pharmaceutical use |
US8802087B2 (en) | 2004-03-22 | 2014-08-12 | Abbott Products Gmbh | Pharmaceutical compositions of lipase-containing products, in particular of pancreation |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
WO2016126970A1 (en) | 2015-02-04 | 2016-08-11 | Abbvie Inc. | Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US10704037B2 (en) | 2005-07-29 | 2020-07-07 | Abbott Products Gmbh | Processes for the manufacture and use of pancreatin |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
US20010046493A1 (en) * | 2000-02-24 | 2001-11-29 | Alex Margolin | Lipase-containing composition and methods of use thereof |
US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
IT1319655B1 (it) | 2000-11-15 | 2003-10-23 | Eurand Int | Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione. |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
ES2421538T3 (es) * | 2003-10-29 | 2013-09-03 | Cystic Fibrosis Foundation Therapeutics Inc | Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor |
US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
AU2006261443A1 (en) * | 2005-06-24 | 2006-12-28 | Novozymes A/S | Proteases for pharmaceutical use |
EP1931317B1 (de) * | 2005-08-15 | 2008-12-24 | Solvay Pharmaceuticals GmbH | Pankreatin-mikropellets geeignet für magensaftresistente überzüge |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
US20100196344A1 (en) * | 2005-10-14 | 2010-08-05 | Cystic Fibrosis Foundation Therapeutics, Inc. | Compositions and methods for treating pancreatic insufficiency |
WO2007053619A2 (en) * | 2005-11-01 | 2007-05-10 | Bio-Cat, Inc. | A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency |
US20080081035A1 (en) * | 2006-10-03 | 2008-04-03 | National Enzyme Company | Therapeutic protease compositions |
US20080199448A1 (en) * | 2007-02-16 | 2008-08-21 | Ross Mairi R | Enzyme composition for improving food digestion |
PL2079445T3 (pl) * | 2007-02-20 | 2016-04-29 | Allergan Pharmaceuticals Int Ltd | Stabilne kompozycje enzymów trawiennych |
US20090068174A1 (en) * | 2007-09-12 | 2009-03-12 | Kansas University Medical Center Research Institute, Inc. | Therapeutic alkaline protease compositions and use in facilitating the transport of agents across the gastrointestinal mucosal lining |
US20090130063A1 (en) * | 2007-11-15 | 2009-05-21 | Solvay Pharmaceuticals Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) * | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US9320780B2 (en) * | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
US11016104B2 (en) * | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
EP2328566A1 (de) * | 2008-09-30 | 2011-06-08 | DSM IP Assets B.V. | Enzymzusammensetzung und deren anwendung bei der behandlung von pankreasinsuffizienz |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
CA2747703C (en) | 2009-01-06 | 2021-06-15 | Curemark Llc | Compositions and methods for the treatment or the prevention of infections by e. coli |
AU2010203709B2 (en) | 2009-01-06 | 2014-05-22 | Galenagen, Llc | Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces |
AU2015252099B2 (en) * | 2009-01-06 | 2017-08-10 | Galenagen, Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
CA2793685A1 (en) * | 2010-03-19 | 2011-09-22 | Aptalis Pharma Canada Inc. | Gastro-resistant enzyme pharmaceutical compositions |
KR101968457B1 (ko) | 2010-10-01 | 2019-04-11 | 앨러간 파마슈티컬스 인터내셔널 리미티드 | 장용 코팅된 저 강도 췌장 리파제 제제 |
ES2673940T3 (es) | 2010-12-22 | 2018-06-26 | Novozymes North America, Inc. | Proceso para producir productos de fermentación a partir de materiales que contienen almidón |
JP5976100B2 (ja) | 2011-04-21 | 2016-08-23 | キュアマーク リミテッド ライアビリティ カンパニー | 神経精神障害の処置のための化合物 |
RU2016119726A (ru) | 2011-08-08 | 2018-11-02 | Апталис Фарма Лтд. | Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты |
IN2014CN04905A (de) * | 2011-12-02 | 2015-09-18 | Novozymes As | |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
PL2897604T3 (pl) | 2012-09-19 | 2018-10-31 | Grespo Ab | Kompozycje do ulepszenia funkcji mózgu |
CA2905159C (en) | 2013-03-15 | 2023-01-03 | Aptalis Pharma Ltd. | Composition containing digestive enzymes and nutrients suitable for enteral administration |
US11939552B2 (en) | 2013-06-24 | 2024-03-26 | Novozymes A/S | Process of recovering oil |
CN105339501A (zh) | 2013-06-24 | 2016-02-17 | 诺维信公司 | 用于从发酵产物过程中回收油的方法以及用于生产发酵产物的方法 |
US10184121B2 (en) | 2013-06-28 | 2019-01-22 | Allergan Pharmaceuticals International Limited | Methods for removing viral contaminants from pancreatic extracts |
AU2014304176A1 (en) * | 2013-07-22 | 2016-02-11 | Aptalis Pharma Ltd. | High potency pancreatin pharmaceutical compositions |
WO2015069677A1 (en) * | 2013-11-05 | 2015-05-14 | Aptalis Pharma Ltd. | High potency pancreatin pharmaceutical compositions |
ES2784227T3 (es) | 2013-08-09 | 2020-09-23 | Allergan Pharmaceuticals Int Ltd | Composición de enzimas digestivos adecuada para la administración entérica |
GB201501081D0 (en) | 2015-01-22 | 2015-03-11 | Cilian Ag | Use of enzymes with a wide pH activity range as medicaments for promoting digestion |
US20200291375A1 (en) * | 2017-09-24 | 2020-09-17 | Bio-Cat, Inc. | Fungal protease mixtures and uses thereof |
FR3079146B1 (fr) | 2018-03-23 | 2020-04-17 | Karim Ioualalen | Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive. |
FR3111559A1 (fr) * | 2020-06-18 | 2021-12-24 | Azurrx Biopharma, Inc. | Formulations non porcines et leurs procédés |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1084431A (en) * | 1964-05-06 | 1967-09-20 | Analyses Et De Rech S Biolog M | Improvements in and relating to lipases |
DE2638088A1 (de) * | 1976-08-24 | 1978-03-02 | Degussa | Verfahren zur herstellung von verbesserten arzneizubereitungen, die lipase nicht-tierischen ursprungs enthalten |
DE4332985A1 (de) * | 1993-09-28 | 1995-03-30 | Konrad Peter Maria Dr Sommer | Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3152958B2 (ja) * | 1991-06-14 | 2001-04-03 | 天野エンザイム株式会社 | 微生物起源リパーゼの安定化組成物及び安定化法 |
US5750104A (en) * | 1996-05-29 | 1998-05-12 | Digestive Care Inc. | High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith |
US6013680A (en) * | 1997-10-21 | 2000-01-11 | Amano Pharmaceutical Co., Ltd. | Digestive enzyme-containing medicament |
-
2002
- 2002-01-10 AR ARP020100070A patent/AR032392A1/es not_active Application Discontinuation
- 2002-01-16 CZ CZ20031900A patent/CZ20031900A3/cs unknown
- 2002-01-16 PL PL02362646A patent/PL362646A1/xx not_active Application Discontinuation
- 2002-01-16 RU RU2003124078/15A patent/RU2003124078A/ru not_active Application Discontinuation
- 2002-01-16 CA CA002434808A patent/CA2434808A1/en not_active Abandoned
- 2002-01-16 EP EP02716661A patent/EP1381386A2/de not_active Withdrawn
- 2002-01-16 NZ NZ527148A patent/NZ527148A/en unknown
- 2002-01-16 BR BR0206521-5A patent/BR0206521A/pt not_active IP Right Cessation
- 2002-01-16 JP JP2002560665A patent/JP2004524838A/ja not_active Withdrawn
- 2002-01-16 SK SK929-2003A patent/SK9292003A3/sk unknown
- 2002-01-16 IL IL15700402A patent/IL157004A0/xx unknown
- 2002-01-16 CN CNB028038894A patent/CN1236817C/zh not_active Expired - Fee Related
- 2002-01-16 WO PCT/EP2002/000374 patent/WO2002060474A2/de not_active Application Discontinuation
- 2002-01-16 HU HU0500560A patent/HUP0500560A3/hu unknown
- 2002-01-16 MX MXPA03005960A patent/MXPA03005960A/es unknown
-
2003
- 2003-07-17 US US10/620,759 patent/US20040057944A1/en not_active Abandoned
- 2003-07-18 NO NO20033261A patent/NO20033261D0/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1084431A (en) * | 1964-05-06 | 1967-09-20 | Analyses Et De Rech S Biolog M | Improvements in and relating to lipases |
DE2638088A1 (de) * | 1976-08-24 | 1978-03-02 | Degussa | Verfahren zur herstellung von verbesserten arzneizubereitungen, die lipase nicht-tierischen ursprungs enthalten |
DE4332985A1 (de) * | 1993-09-28 | 1995-03-30 | Konrad Peter Maria Dr Sommer | Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch, Week 9305 Derwent Publications Ltd., London, GB; Class B04, AN 1993-042580 XP002232576 & JP 04 370096 A (AMANO PHARM KK), 22. Dezember 1992 (1992-12-22) * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8802087B2 (en) | 2004-03-22 | 2014-08-12 | Abbott Products Gmbh | Pharmaceutical compositions of lipase-containing products, in particular of pancreation |
WO2005115445A1 (en) | 2004-05-24 | 2005-12-08 | Novozymes A/S | Enzymes for pharmaceutical use |
JP2008500055A (ja) * | 2004-05-24 | 2008-01-10 | ノボザイムス アクティーゼルスカブ | 医薬用途のための酵素 |
WO2006044529A1 (en) * | 2004-10-14 | 2006-04-27 | Altus Pharmaceuticals Inc. | Compositions containing lipase; protease and amylase for treating pancreatic insufficiency |
CN101068565B (zh) * | 2004-10-14 | 2010-11-17 | 胞囊纤维化基础治疗公司 | 治疗胰腺功能不全的包含脂酶、蛋白酶和淀粉酶的组合物 |
EP2198880A1 (de) * | 2004-10-14 | 2010-06-23 | Altus Pharmaceuticals Inc. | Zusammensetzung enthaltend Lipase, Protease und Amylase zur Behandlung von Pankreasinsuffizienz |
US7718169B2 (en) | 2004-10-14 | 2010-05-18 | Cystic Fibrosis Foundations Therapeutics, Inc. | Compositions and methods for treating pancreatic insufficiency |
WO2006136159A3 (en) * | 2005-06-24 | 2007-04-12 | Novozymes As | Lipases for pharmaceutical use |
WO2006136161A3 (en) * | 2005-06-24 | 2007-07-05 | Novozymes As | Amylases for pharmaceutical use |
WO2006136159A2 (en) * | 2005-06-24 | 2006-12-28 | Novozymes A/S | Lipases for pharmaceutical use |
WO2006136161A2 (en) * | 2005-06-24 | 2006-12-28 | Novozymes A/S | Amylases for pharmaceutical use |
US8017351B2 (en) | 2005-06-24 | 2011-09-13 | Novozymes A/S | Amylases for pharmaceutical use |
US10704037B2 (en) | 2005-07-29 | 2020-07-07 | Abbott Products Gmbh | Processes for the manufacture and use of pancreatin |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US7998476B2 (en) | 2006-11-22 | 2011-08-16 | Standard Biologics, Inc. | Method of treatment using Aspergillus oryzae protease |
WO2008079685A2 (en) * | 2006-12-21 | 2008-07-03 | Novozymes A/S | Lipase variants for pharmaceutical use |
EP2455462A2 (de) | 2006-12-21 | 2012-05-23 | Novozymes A/S | Lipasevarianten zur pharmazeutischen Verwendung |
EP2455461A2 (de) | 2006-12-21 | 2012-05-23 | Novozymes A/S | Lipasevarianten zur pharmazeutischen Verwendung |
US8273348B2 (en) | 2006-12-21 | 2012-09-25 | Novozymes A/S | Lipase variants for pharmaceutical use |
EP2455459A2 (de) | 2006-12-21 | 2012-05-23 | Novozymes A/S | Lipasevarianten zur pharmazeutischen Verwendung |
US9029115B2 (en) | 2006-12-21 | 2015-05-12 | Novozymes A/S | Lipase variants for pharmaceutical use |
EP2455460A2 (de) | 2006-12-21 | 2012-05-23 | Novozymes A/S | Lipasevarianten zur pharmazeutischen Verwendung |
US9539311B2 (en) | 2006-12-21 | 2017-01-10 | Novozymes A/S | Lipase variants for pharmaceutical use |
EP2261328A1 (de) | 2006-12-21 | 2010-12-15 | Novozymes A/S | Lipase-varianten zur pharmazeutischen Verwendung |
WO2008079685A3 (en) * | 2006-12-21 | 2008-11-06 | Novozymes As | Lipase variants for pharmaceutical use |
US8455235B2 (en) | 2007-12-04 | 2013-06-04 | Novozymes A/S | Protease variants for pharmaceutical use |
WO2009083607A1 (en) * | 2008-01-03 | 2009-07-09 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders |
WO2016126970A1 (en) | 2015-02-04 | 2016-08-11 | Abbvie Inc. | Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency |
Also Published As
Publication number | Publication date |
---|---|
EP1381386A2 (de) | 2004-01-21 |
HUP0500560A3 (en) | 2006-06-28 |
US20040057944A1 (en) | 2004-03-25 |
AR032392A1 (es) | 2003-11-05 |
CN1487837A (zh) | 2004-04-07 |
NO20033261L (no) | 2003-07-18 |
HUP0500560A2 (hu) | 2005-09-28 |
CA2434808A1 (en) | 2002-08-08 |
SK9292003A3 (en) | 2003-12-02 |
MXPA03005960A (es) | 2003-09-05 |
IL157004A0 (en) | 2004-02-08 |
NO20033261D0 (no) | 2003-07-18 |
RU2003124078A (ru) | 2005-01-27 |
WO2002060474A3 (de) | 2003-10-30 |
CN1236817C (zh) | 2006-01-18 |
JP2004524838A (ja) | 2004-08-19 |
BR0206521A (pt) | 2004-02-17 |
NZ527148A (en) | 2005-01-28 |
PL362646A1 (en) | 2004-11-02 |
CZ20031900A3 (cs) | 2003-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002060474A2 (de) | Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion | |
DE69634248T2 (de) | Zusammensetzungen zur verbesserung der verdaulichkeit und ausnutzung von nähestoffen | |
DE2626109C2 (de) | ||
DE502007010071C5 (de) | Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden | |
EP1162995B1 (de) | Enzyme zur behandlung von diabetes mellitus typ i | |
DE60007001T2 (de) | Neurotoxine zur behandlung von pankreatischen krankheiten | |
EP2391382B1 (de) | Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs | |
EP2445510B1 (de) | Zusammensetzung zur behandlung von degenerativen gelenkerkrankungen | |
DE60004879T2 (de) | Tierfuttermittelzusatz | |
DE202006021153U1 (de) | Stabile, haltbare Granulate mit aktiven Mitteln | |
DD300405A5 (de) | Pharmazeutische rezepturen | |
EP1858536A2 (de) | Arzneimittel aus pflanzenextrakten als lipaseinhibitor | |
WO2003051345A2 (de) | Verwendung von verdauungsenzymgemischen zur behandlung pathologischer bakterieller überwucherung des dünndarms von säugetieren und menschen | |
DE60304723T2 (de) | VERZWEIGTE ALPHA-GLUCANE FüR DAS GEWICHTSMANAGEMENT | |
WO2002036156A1 (de) | Verwendung von aus ciliaten gewonnenen enzymen als verdauungsfördernde arzneimittel | |
EP3525769B1 (de) | Schmelztablette enthaltend burlulipase und daraus hergestellte pharmazeutische zusammensetzung | |
DE2935546C2 (de) | Diätetische Lebensmittel mit Monoglyceriden von Fettsäuren | |
DE102006036285A1 (de) | Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms | |
DE60037197T2 (de) | Verwendung funktioneller oraler präparate | |
DE10144711A1 (de) | Neue Gemische mikrobieller Enzyme | |
EP1687014A1 (de) | Verwendung einer zusätzlich fermentierten getreideschlempe zur vorbeugung und/oder behandlung erhähter blutzucker-werte | |
DE2006514A1 (de) | Neue proteolytische enzymatische Produkte, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE4236064C2 (de) | Selektiv-toxisches Mittel und seine Verwendung | |
EP0341527A2 (de) | Mittel zur Wachstumssteigerung bei Tieren | |
DE2315006A1 (de) | Pankreasenzympraeparat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200304986 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/005960 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002716661 Country of ref document: EP Ref document number: PV2003-1900 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2434808 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037009470 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 157004 Country of ref document: IL Ref document number: 1-2003-500631 Country of ref document: PH Ref document number: 10620759 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9292003 Country of ref document: SK Ref document number: 028038894 Country of ref document: CN Ref document number: 2002560665 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002247634 Country of ref document: AU Ref document number: 1134/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 527148 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037009470 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-1900 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2002716661 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 527148 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 527148 Country of ref document: NZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002716661 Country of ref document: EP |